These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15370252)

  • 1. Detection and possible prognostic relevance of p53 gene mutations in diffuse large B-cell lymphoma. An analysis of 51 cases and review of the literature.
    Kerbauy FR; Colleoni GW; Saad ST; Regis Silva MR; Correa Alves A; Aguiar KC; Albuquerque DM; Kobarg J; Seixas MT; Kerbauy J
    Leuk Lymphoma; 2004 Oct; 45(10):2071-8. PubMed ID: 15370252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma.
    Hiraga J; Kinoshita T; Ohno T; Mori N; Ohashi H; Fukami S; Noda A; Ichikawa A; Naoe T
    Int J Hematol; 2006 Oct; 84(3):248-55. PubMed ID: 17050200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas.
    Leroy K; Haioun C; Lepage E; Le Métayer N; Berger F; Labouyrie E; Meignin V; Petit B; Bastard C; Salles G; Gisselbrecht C; Reyes F; Gaulard P;
    Ann Oncol; 2002 Jul; 13(7):1108-15. PubMed ID: 12176791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
    Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma.
    Koduru PR; Raju K; Vadmal V; Menezes G; Shah S; Susin M; Kolitz J; Broome JD
    Blood; 1997 Nov; 90(10):4078-91. PubMed ID: 9354678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
    Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
    J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of BCL6, MYC, P53 genes abnormalities for the prognosis of diffuse large B-cell lymphoma].
    Gao P; Li Q; Wang Z; Yan F; Lu C; Cao X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Oct; 31(5):628-31. PubMed ID: 25297597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
    Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
    Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA sequence profile of TP53 gene mutations in childhood B-cell non-Hodgkin's lymphomas: prognostic implications.
    Klumb CE; Furtado DR; de Resende LM; Carriço MK; Coelho AM; de Meis E; Maia RC; Rumjanek FD
    Eur J Haematol; 2003 Aug; 71(2):81-90. PubMed ID: 12890146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.
    Barrans SL; Carter I; Owen RG; Davies FE; Patmore RD; Haynes AP; Morgan GJ; Jack AS
    Blood; 2002 Feb; 99(4):1136-43. PubMed ID: 11830458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study.
    Kramer MH; Hermans J; Parker J; Krol AD; Kluin-Nelemans JC; Haak HL; van Groningen K; van Krieken JH; de Jong D; Kluin PM
    J Clin Oncol; 1996 Jul; 14(7):2131-8. PubMed ID: 8683246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations of p53, c-kit, K-ras, and beta-catenin gene in non-Hodgkin's lymphoma of adrenal gland.
    Nakatsuka S; Hongyo T; Syaifudin M; Nomura T; Shingu N; Aozasa K
    Jpn J Cancer Res; 2002 Mar; 93(3):267-74. PubMed ID: 11927008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.
    Xu-Monette ZY; Zhang S; Li X; Manyam GC; Wang XX; Xia Y; Visco C; Tzankov A; Zhang L; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Young KH
    Aging (Albany NY); 2016 Feb; 8(2):345-65. PubMed ID: 26878872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma.
    Young KH; Weisenburger DD; Dave BJ; Smith L; Sanger W; Iqbal J; Campo E; Delabie J; Gascoyne RD; Ott G; Rimsza L; Müller-Hermelink HK; Jaffe ES; Rosenwald A; Staudt LM; Chan WC; Greiner TC
    Blood; 2007 Dec; 110(13):4396-405. PubMed ID: 17881637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.
    Young KH; Leroy K; Møller MB; Colleoni GW; Sánchez-Beato M; Kerbauy FR; Haioun C; Eickhoff JC; Young AH; Gaulard P; Piris MA; Oberley TD; Rehrauer WM; Kahl BS; Malter JS; Campo E; Delabie J; Gascoyne RD; Rosenwald A; Rimsza L; Huang J; Braziel RM; Jaffe ES; Wilson WH; Staudt LM; Vose JM; Chan WC; Weisenburger DD; Greiner TC
    Blood; 2008 Oct; 112(8):3088-98. PubMed ID: 18559976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
    Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
    Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas.
    Zhang A; Ohshima K; Sato K; Kanda M; Suzumiya J; Shimazaki K; Kawasaki C; Kikuchi M
    Pathol Int; 1999 Dec; 49(12):1043-52. PubMed ID: 10632924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma.
    Wilson KS; Sehn LH; Berry B; Chhanabhai M; Fitzgerald CA; Gill KK; Klasa R; Skinnider B; Sutherland J; Connors JM; Gascoyne RD
    Leuk Lymphoma; 2007 Jun; 48(6):1102-9. PubMed ID: 17577773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
    Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
    Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Investigation for pathological interpretation criteria and its prognostic value for P53 expression in Chinese diffuse large B-cell lymphoma].
    Shi YF; Gao ZF; Li XH; Guo LG; Zheng QL; Long MP; Deng LJ; Du TT; Jia L; Zhao W; Song XX; Li M
    Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1010-1015. PubMed ID: 36709106
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.